These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6127517)

  • 21. Isosorbide dinitrate in portal hypertensive patients.
    Vorobioff J; Picabea E; Gamen M; Villavicencio R
    J Hepatol; 1992 Nov; 16(3):387. PubMed ID: 1487620
    [No Abstract]   [Full Text] [Related]  

  • 22. [Beta blockaders and portal hypertension].
    Lebrec D
    Rev Prat; 1989 Apr; 39(13):1154-8. PubMed ID: 2567529
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
    Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
    J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemoptysis secondary to bronchial varices associated with alcoholic liver cirrhosis and portal hypertension.
    Youssef AI; Escalante-Glorsky S; Bonnet RB; Chen YK
    Am J Gastroenterol; 1994 Sep; 89(9):1562-3. PubMed ID: 8079940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Spontaneous spleen rupture and liver cirrhosis].
    Molina M; Ortega G; de Paco M; Buendía JL
    Med Clin (Barc); 1995 Feb; 104(5):199. PubMed ID: 7877387
    [No Abstract]   [Full Text] [Related]  

  • 26. Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis.
    Koshy A; Hadengue A; Lee SS; Jiron MI; Lebrec D
    Clin Pharmacol Ther; 1987 Sep; 42(3):295-8. PubMed ID: 3621783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Portal hypertension: value of combination of nitrate derivatives and beta blockers for better prevention?].
    Oberti F; Calès P
    Gastroenterol Clin Biol; 1995 Mar; 19(3):328-31. PubMed ID: 7781957
    [No Abstract]   [Full Text] [Related]  

  • 28. Portal hypertension, propranolol, and hepatic encephalopathy.
    Lancet; 1982 Oct; 2(8303):879-80. PubMed ID: 6126739
    [No Abstract]   [Full Text] [Related]  

  • 29. Cirrhotic portal hypertension: current and future medical therapy for primary and secondary prevention of variceal bleeding.
    Laleman W; Nevens F
    Minerva Med; 2006 Aug; 97(4):325-45. PubMed ID: 17008837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of propranolol in portal hypertension. Conventional and long acting formulations.
    Hayes PC
    Drugs; 1989; 37 Suppl 2():70-3; discussion 74-6. PubMed ID: 2680433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
    Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
    Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound].
    Monnin JL; Vinel JP; Le Quellec A; Pascal JP; Taourel P; Bruel JM; Blanc F; Michel H; Ciurana AJ
    Gastroenterol Clin Biol; 1992; 16(10):745-50. PubMed ID: 1478400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
    Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Association of extrahepatic aneurysm of the hepatic artery and aneurysm of the portal trunk in a patient with liver cirrhosis].
    Rifflet H; Person B; Oberti F; Aubé C; Papon X; Calès P
    Gastroenterol Clin Biol; 1995 Nov; 19(11):958-60. PubMed ID: 8746063
    [No Abstract]   [Full Text] [Related]  

  • 35. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group.
    Conn HO; Grace ND; Bosch J; Groszmann RJ; Rodés J; Wright SC; Matloff DS; Garcia-Tsao G; Fisher RL; Navasa M
    Hepatology; 1991 May; 13(5):902-12. PubMed ID: 2029994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension.
    Pagliaro L; Pasta L; D'Amico G; Filippazzo MG; Tinè F; Morabito A; Ferrari A; Marenco G; De Pretis G
    N Engl J Med; 1986 Jan; 314(4):244-5. PubMed ID: 3510389
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk of hepatic encephalopathy in patients taking propranolol for portal hypertension.
    Reding P
    Lancet; 1982 Sep; 2(8297):550. PubMed ID: 6125697
    [No Abstract]   [Full Text] [Related]  

  • 38. [Abdominal varices in computerized axial tomography].
    Garza Trasobares E; Méndez A; Peña JM; García-Alegría J; Sánchez Mejías F
    Rev Esp Enferm Apar Dig; 1987 Jan; 71(1):57-8. PubMed ID: 3563035
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
    Bañares R; Moitinho E; Matilla A; García-Pagán JC; Lampreave JL; Piera C; Abraldes JG; De Diego A; Albillos A; Bosch J
    Hepatology; 2002 Dec; 36(6):1367-73. PubMed ID: 12447861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transjugular intrahepatic portosystemic shunt before hepatic surgery in a patient with cirrhosis and portal hypertension: case report].
    Chalret Du Rieu M; Carrere N; Bureau C; Lagarde S; Otal P; Pradere B
    J Chir (Paris); 2009 Apr; 146(2):191-4. PubMed ID: 19535077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.